Alex Franzusoff, Ph.D.
Chief Executive Officer
Dr. Franzusoff joined PACT Pharma in January 2017. Previously, he was consulting for several private and public biotech/pharma companies in the I-O space, in addition to his role as founder and CEO of Krypton Immuno-oncology. At Bavarian Nordic, he worked at the forefront of the electrified I-O space as SVP R&D, which resulted in the $1B deal with BMS for Prostvac, its Ph3 cancer immunotherapy product. He had returned to California for that role, from Boston, after serving as Chief Executive Officer and Board Director for AZTherapies, developing Alzheimer’s therapies based on re-purposing previously approved drugs via the 505(b)2 pathway for Phase 3 studies. He previously led the venture-backed Permeon Biologics as President and a member of the board of directors. Dr. Franzusoff’s career in the biotechnology industry was launched with the co-founding of the biotech GlobeImmune, Inc., where he served as Vice President of Research & Development for immunotherapy against cancer & infectious diseases.
Dr. Franzusoff trained as a Postdoctoral Fellow with the Nobel Laureate, Dr. Randy Schekman, at the University of California, Berkeley after earning his Ph.D. in Biochemistry at SUNY at Stony Brook. He was a tenured Associate Professor at the University of Colorado, School of Medicine until 2004.
President and Chief Technology Officer
Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations. Most recently, he served as Executive Vice President, Technical Operations at Kite, a Gilead Company, since March of 2016. During this time Mr. Moore was responsible for overseeing the process development, manufacturing, quality and supply chain for the launch of Yescarta®, one of the first CAR T therapies to be developed, manufactured and commercialized, as well as advancement of the Kite pipeline. In addition, Mr. Moore globally expanded the biopharmaceutical operations to serve and support the US, EU, as well as key partners in Asia.
Prior to Kite, Mr. Moore served as the Senior Vice President, Head of Global Technical Operations – Biologics of Genentech, Inc. and as a member of the Genentech Executive Committee since 2010. In this role, Mr. Moore oversaw global leadership for more than 7,500 professionals across 10 internal sites and over 37 contract manufacturing organizations, as well as global manufacturing and end-to-end quality supply performance of more than 20 biological product families. Prior to that, Mr. Moore was Genentech’s Senior Vice President, Global Supply Chain and Global Engineering from 2007 to 2010. Previously, Mr. Moore served as Vice President, Operations at ZLB Behring (formerly Aventis Behring). He is currently a member of ISPE, PDA and has been a part of the Executive Committee of BioPhorum and serves as a Board member for Cerus. Mr. Moore received a B.S. in Chemical Engineering from Tulsa University and a M.S. in Engineering Management from Northwestern University.
Atulya Agarwal, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Atulya Agarwal, J.D., Ph.D., serves as PACT’s Chief Legal and Compliance Officer, Corporate Secretary, with oversight of all corporate legal functions, including compliance, IP and licensing-related activities, as well as oversight of HR matters. Dr. Agarwal is a seasoned attorney with more than 25 years in the biotech and pharmaceutical industries. Fifteen of those were spent at Genentech, where he held various roles of increasing responsibility, including the Head of IP Licensing and Business Strategy as well as the Head of Patents for Genentech’s Oncology franchise.
Dr. Agarwal also has held the positions of Chief IP officer at Elan Pharmaceuticals and Partner at Dickstein Shapiro, where his practice focused on all aspects of IP strategy, including IP diligence, contract drafting and negotiation, IP enforcement, and U.S. and foreign patent prosecution. Dr. Agarwal received a J.D. from Santa Clara University School of Law, a Ph.D. in Biochemistry from Boston University School of Medicine and a B.S. in Biochemistry from the Pennsylvania State University.
Chief Financial Officer
Uneek Mehra joins PACT as Chief Financial Officer. Uneek has over 23 years of experience in strategy, finance and operations with his most recent role as Chief Financial officer at Proteus Digital Health. At Proteus, Uneek helped scale the company from 150 employees to ~300 employees, managed investor relationships and partnered with the Board & Executive team to help launch the first-ever Digital Medicine.
Previously, Uneek has had extensive experience in senior finance roles with Novartis, IBM and Citibank. At Novartis, he worked in roles with increasing responsibilities in the Corporate Finance, Business Development and Treasury departments across US, Switzerland and China. He also served as CFO of two of the largest specialty Medicines Franchises within the Novartis US business.
Uneek has an MBA in Strategy and Leadership from IMD, Lausanne, Switzerland as well as a Masters in Finance and a Bachelors in Engineering from premier universities in India.
Senior Vice President, Manufacturing
Greg Yedinak joins PACT as Sr. Vice President of Manufacturing. Greg has over 30 years’ experience in pharmaceutical, Biologics, and Medical Device manufacturing and operations. Prior to joining PACT, Greg was VP of Drug Product and Device operations at Versartis, where he was responsible for the somavaratan Drug product, autoinjector development, and production programs. Before Versartis, Greg held various executive and leadership positions at Zosano, Nuvelo, Abgeneix/Amgen, and Genentech, where he was integral to the strategic production planning, process development, implementation, and production of numerous clinical and commercial products and devices. Greg received a BS in Biological Sciences from the University of California-Irvine.
Gregg Fine, M.D.
Vice President, Clinical Development
Gregg Fine, M.D., joins PACT as Vice President, Head of Clinical Development and is responsible for the clinical development strategy and medical oversight of the Company’s portfolio. Gregg has more than a decade of experience in drug development and most recently served as the Development Leader for Genentech’s RNA-based personalized neoantigen cancer vaccine program. Previously he served as the Global Development Team Leader at Roche for the genitourinary franchise of TECENTRIQ® and led the program from Phase I through the initial BLA approval for bladder cancer and beyond to expansion in Phase I-III studies in RCC and prostate cancer. Gregg also worked on pivotal programs for GAZYVA® and RITUXAN®.
Dr. Fine obtained his baccalaureate from Colgate University and his medical degree from the University of Vermont College of Medicine. He completed his residency in Internal Medicine at Yale-New Haven Hospital and his fellowship in Hematology/Oncology at the Beth Israel Deaconess Medical Center/Harvard Cancer Center where his area of research interest was in clinical informatics. Dr. Fine is board certified in medical oncology.
Jeroen Grasman, M.B.A.
Vice President, Finance and Corporate Treasurer
Jeroen Grasman, M.B.A. joins PACT as Vice President, Finance and Corporate Treasurer is responsible for the Company’s finance, accounting, information technology, facility and procurement functions. Jeroen has more than 20 years of experience in finance and operations, most recently as Vice President, Finance at Intarcia Therapeutics. At Intarcia, he served as finance head for manufacturing and global commercialization of its MediciTM Drug Delivery System. Prior to Intarcia, Mr. Grasman spent 11 years at Genentech-Roche, where he held positions of increasing responsibility in Strategic Planning, Business Development Finance, R&D Finance and finally as global finance head for Biologics Manufacturing at Roche. Mr. Grasman received an MBA at Harvard Business School and an MS in Statistics and Operations Research at the University of Groningen.
Stefanie Mandl, Ph.D.
Vice President, Translational Immunology
Stefanie Mandl, Ph.D. has been appointed to the role of Vice President, Translational Immunology. She is responsible for leading PACT’s personalized neoTCR-T cell engineering, adoptive T cell therapy product characterization and immune monitoring/biomarker development. Dr. Mandl has extensive experience in the development of immunotherapies for the treatment of cancer and infectious disease. Dr. Mandl joined PACT Pharma in April of 2017 as the Senior Director, Tumor Immunology. Prior to PACT, she was the Senior Director, Immunology at Cidara Therapeutics, to direct scientific development of the CloudbreakTM platform for the treatment of infectious disease. Before Cidara, Stefanie worked 9 years at Bavarian Nordic, most recently as the Director, Pre-clinical Oncology Research. Dr. Mandl’s experience in cancer immunotherapy began in Berlin, where she received her MS in Biology from Freie Universität Berlin, then earned her PhD in Immunology at the University of California San Francisco and trained as a postdoctoral fellow at Stanford University.
Maria Simon, M.B.A
Vice President, Human Resources
Maria Simon, M.B.A. joins PACT as Vice President of Human Resources with responsibility for the Company’s people strategy. She has over 25 years experiences in Human Resources in a variety of industries from high tech, pharmaceutical, to biotech. Most recently, Maria led the human resources function at Audentes Therapeutics. She also worked at Medivation (becoming Pfizer after the acquisition) providing HR leadership and oversight to the Chief Medical Officer and Senior VP of Technical Operations and Regulatory, three different Johnson and Johnson Operating Companies in the Medical Device Sector, Symantec Corp, PeopleSoft, and SGI leading various teams within Human Resources. Maria has her undergraduate and graduate degrees from Notre Dame de Namur University.
Vice President, Quality Control
Will White joined PACT Pharma in 2018 with over 30 years Quality Control management experience in biopharmaceutical and diagnostic industries producing vaccines, recombinant monoclonal antibodies and proteins, oligonucleotides products, and drug/device combination products. Prior to joining PACT, Will consulted for several years in the biopharmaceutical industry leveraging his extensive experience managing all aspects of product quality analysis. His industry experience includes 11 years at MedImmune focused on FluMist® and a pandemic influenza vaccine. Will also spent 14 years in a number of roles with increasing responsibility within Genentech Quality organization, working on both clinical and commercial products. Will received his baccalaureate in Biological Sciences from University of California, Santa Barbara.
Vice President, Program and Portfolio Management
Susan Whitehead has spent over 18 years in the pharmaceutical, medical device and biotechnology arena where she’s played key roles in early and late stage development. Susan joined Pact Pharma in 2018 as Senior Director, Program Operations and was promoted to VP, Program & Portfolio Management in 2019.
With her BS in Chemistry from Michigan State University, Susan began her biotech career at Sunesis Pharmaceuticals, where she soon transitioned from the lab to work in Project Management. Susan served as Project Manager, Program Manager/Project Leader and Department Head at multiple organizations, including ALZA Pharmaceuticals & Conor Medsystems (both Johnson & Johnson companies), BiPar Sciences (a Sanofi Aventis company), Bavarian Nordic and again at Sunesis Pharmaceuticals. Susan has managed numerous on-time regulatory filings in acute pain, cardiology and oncology. Susan has also worked in Medical Affairs Operations and served as Global Head of Operations at Caligor Rx, where she earned General Manager responsibility for oversight of their Global Access Programs Business Unit.